iSAM Funds UK Ltd Acquires New Stake in Henry Schein, Inc. $HSIC

iSAM Funds UK Ltd acquired a new stake in Henry Schein, Inc. (NASDAQ:HSIC) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 45,335 shares of the company’s stock, valued at approximately $3,009,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Ameriprise Financial Inc. grew its holdings in shares of Henry Schein by 3,275.2% during the second quarter. Ameriprise Financial Inc. now owns 2,266,858 shares of the company’s stock worth $165,594,000 after buying an additional 2,199,695 shares in the last quarter. Norges Bank purchased a new position in shares of Henry Schein in the second quarter worth about $89,476,000. M.D. Sass LLC acquired a new position in Henry Schein during the second quarter worth about $79,201,000. Schroder Investment Management Group boosted its position in Henry Schein by 149.3% during the second quarter. Schroder Investment Management Group now owns 1,563,899 shares of the company’s stock worth $114,243,000 after acquiring an additional 936,471 shares during the last quarter. Finally, Bank of America Corp DE grew its stake in Henry Schein by 204.2% during the 2nd quarter. Bank of America Corp DE now owns 995,375 shares of the company’s stock valued at $72,712,000 after acquiring an additional 668,182 shares in the last quarter. Institutional investors and hedge funds own 96.62% of the company’s stock.

Insiders Place Their Bets

In other news, Director Philip A. Laskawy sold 2,844 shares of the stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $80.36, for a total transaction of $228,543.84. Following the completion of the transaction, the director directly owned 21,961 shares in the company, valued at approximately $1,764,785.96. This represents a 11.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Mark E. Mlotek sold 5,925 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $80.80, for a total value of $478,740.00. Following the transaction, the executive vice president owned 80,554 shares of the company’s stock, valued at approximately $6,508,763.20. This represents a 6.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 104,556 shares of company stock worth $8,476,351 in the last three months. 1.08% of the stock is owned by insiders.

Henry Schein Stock Performance

Henry Schein stock opened at $75.57 on Friday. The firm has a 50 day simple moving average of $78.21 and a 200-day simple moving average of $72.83. The stock has a market cap of $8.67 billion, a price-to-earnings ratio of 23.11, a price-to-earnings-growth ratio of 2.22 and a beta of 0.88. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.38 and a quick ratio of 0.76. Henry Schein, Inc. has a 1-year low of $60.56 and a 1-year high of $89.29.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Tuesday, February 24th. The company reported $1.34 EPS for the quarter, beating the consensus estimate of $1.30 by $0.04. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. The firm had revenue of $3.44 billion for the quarter, compared to analyst estimates of $3.34 billion. During the same quarter in the previous year, the company earned $1.19 EPS. The business’s revenue for the quarter was up 7.7% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. On average, analysts expect that Henry Schein, Inc. will post 4.74 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have commented on HSIC. Robert W. Baird set a $100.00 price objective on shares of Henry Schein and gave the company an “outperform” rating in a report on Monday, February 23rd. Wells Fargo & Company boosted their target price on Henry Schein from $76.00 to $87.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 25th. Leerink Partners restated a “market perform” rating on shares of Henry Schein in a research report on Monday. Morgan Stanley increased their price target on Henry Schein from $58.00 to $61.00 and gave the company an “underweight” rating in a report on Wednesday, February 25th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Henry Schein in a research report on Monday, December 29th. Six analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $85.58.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.